Observational studyBlood cancer journal2022
Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group.
Observational study in Blood cancer journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Ten tips for kidney biopsy in cancer patients.Clinical kidney journal · 2026Review
- Living Donor Kidney Transplantation in High-Recurrence Kidney Diseases: Precision Risk Stratification and Management.Kidney international reports · 2026Review
- Systematic Review of Kidney Transplant Outcomes in Monoclonal Ig Deposition Disease.Kidney international reports · 2026Article
- Pathogenesis and kidney prognosis of renal amyloidosis.Cellular and molecular life sciences : CMLS · 2026Review
- Monoclonal gammopathy of renal significance from a hematologic perspective.Hematology. American Society of Hematology. Education Program · 2025Review
- Management recommendations for kidney transplantation in patients with plasma cell dyscrasia.Kidney international · 2025Review
- Cardiac Amyloidosis: Tribulations and New Frontiers.Journal of personalized medicine · 2025Review
- Kidney Transplantation in Patients with Multiple Myeloma: Current Evidence, Challenges, and Future Directions.International journal of molecular sciences · 2025Review
- Ten tips for an onco-nephrology clinic.Clinical kidney journal · 2025Review
- AL Amyloidosis: Current Treatment and Outcomes.Advances in hematology · 2025Review
- Renal manifestations of MGUS.Hematology. American Society of Hematology. Education Program · 2024Review
- Renal Transplant Outcomes in Plasma Cell Dyscrasias and AL Amyloidosis after Treatment with Daratumumab.Journal of clinical medicine · 2024Article
- Role of Palliative Care in the Supportive Management of AL Amyloidosis-A Review.Journal of clinical medicine · 2024Review
- Renal AL Amyloidosis: Updates on Diagnosis, Staging, and Management.Journal of clinical medicine · 2024Review
- Lung Transplantation for Pulmonary AL Amyloidosis.Transplantation direct · 2024Article
- Onconephrology 2022: An Update.Kidney360 · 2023Review
- Recent Updates in the Diagnosis and Management of Kidney Diseases in Multiple Myeloma.Indian journal of nephrologyReview
- Systemic amyloid light-chain amyloidosis beyond ANDROMEDA: Diagnostic challenges and therapeutic updates.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 8 institutions in 5 countries.
Funding
Abstract
Effective systemic therapies suppress toxic light chain production leading to an increased proportion of patients with light chain (AL) amyloidosis who survive longer albeit with end-stage renal disease. There is a critical need to identify patients in this population who benefit from renal transplantation. This multicenter, observational study from five countries includes 237 patients with AL amyloidosis who underwent renal transplantation between 1987 and 2020. With a median follow-up of 8.5 years, the median overall survival from renal transplantation was 8.6 years and was significantly longer in patients with complete and very good partial hematologic responses (CR + VGPR) compared to less than VGPR (9 versus 6.8 years; HR: 1.5, P = 0.04 [95% CI: 1-2.1]) at renal transplantation. Median graft survival was 7.8 years and was better in the CR + VGPR group (8.3 vs 5.7 years, HR: 1.4, P = 0.05 [95% CI: 1-2]). The frequency and time to amyloid recurrence in the graft was also lower (16% vs 37%, p = 0.01) and longer (median time not achieved vs 10 years, p = 0.001) in the CR + VGPR group. Comparing CR vs. VGPR there was no difference in overall or graft survival. Although 69 patients (29%) experienced hematologic relapse, treatment effectively prevented graft loss in the majority (87%). Renal transplantation in selected AL amyloidosis patients is associated with extended overall and renal graft survival. Patients with hematologic CR or VGPR have the most favorable outcomes, and these patients should be considered for renal transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.